Sebastian Spencer* and Robert Desborough
Volume4-Issue10
Dates: Received: 2023-10-10 | Accepted: 2023-10-14 | Published: 2023-10-16
Pages: 1422-1424
Abstract
The burden of Chronic Kidney Disease (CKD) remains a growing public health problem. In 2019, the worldwide prevalence was estimated at 7.2 to 13.4%, with CKD incidence, prevalence, mortality and disability-adjusted life years having risen by at least 20% from 2007 through 2017 [1].
FullText HTML
FullText PDF
DOI: 10.37871/jbres1812
Certificate of Publication
Copyright
© 2023 Spencer S, et al. Distributed under Creative Commons CC-BY 4.0 
How to cite this article
Spencer S, Desborough R. Unveiling the Untapped Potential: Cystatin C Testing in Kidney Function Assessment. J Biomed Res Environ Sci. 2023 Oct 16; 4(10): 1422-1424. doi: 10.37871/jbres1812, Article ID: JBRES1812, Available at: https://www. jelsciences.com/articles/jbres1812.pdf
Subject area(s)
References
- Kidney Disease Improving Global Outcomes (KDIGO). Controversies Conference on Early Identification & Intervention in CKD. 2019.
- UK Renal Registry (UKRR). 25th Annual Report. 2021.
- Public Health England (PHE). Chronic Kidney Disease Prevalence Model. 2014.
- Delgado C, Baweja M, Crews DC, Eneanya ND, Gadegbeku CA, Inker LA, Mendu ML, Miller WG, Moxey-Mims MM, Roberts GV, St Peter WL, Warfield C, Powe NR. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. J Am Soc Nephrol. 2021 Dec 1;32(12):2994-3015. doi: 10.1681/ASN.2021070988. Epub 2021 Dec 1. PMID: 34556489; PMCID: PMC8638402.
- Shlipak MG, Wassel Fyr CL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA, Satterfield S, Cummings SR, Newman AB, Fried LF. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol. 2006 Jan;17(1):254-61. doi: 10.1681/ASN.2005050545. Epub 2005 Nov 2. PMID: 16267155.
- Chen DC, Lees JS, Lu K, Scherzer R, Rutherford E, Mark PB, Kanaya AM, Shlipak MG, Estrella MM. Differential Associations of Cystatin C Versus Creatinine-Based Kidney Function With Risks of Cardiovascular Event and Mortality Among South Asian Individuals in the UK Biobank. J Am Heart Assoc. 2023 Feb 7;12(3):e027079. doi: 10.1161/JAHA.122.027079. Epub 2023 Jan 25. PMID: 36695320; PMCID: PMC9973614.
- Lees JS, Rutherford E, Stevens KI, Chen DC, Scherzer R, Estrella MM, Sullivan MK, Ebert N, Mark PB, Shlipak MG. Assessment of Cystatin C Level for Risk Stratification in Adults With Chronic Kidney Disease. JAMA Netw Open. 2022 Oct 3;5(10):e2238300. doi: 10.1001/jamanetworkopen.2022.38300. PMID: 36282503; PMCID: PMC9597396.
- Lees JS, Welsh CE, Celis-Morales CA, Mackay D, Lewsey J, Gray SR, Lyall DM, Cleland JG, Gill JMR, Jhund PS, Pell J, Sattar N, Welsh P, Mark PB. Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease. Nat Med. 2019 Nov;25(11):1753-1760. doi: 10.1038/s41591-019-0627-8. Epub 2019 Nov 7. Erratum in: Nat Med. 2020 Aug;26(8):1308. PMID: 31700174; PMCID: PMC6858876.
- Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakai NA, Safford MM, Zhang X, Muntner P, Warnock D. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA. 2011 Apr 20;305(15):1545-52. doi: 10.1001/jama.2011.468. Epub 2011 Apr 11. PMID: 21482744; PMCID: PMC3697771.
- Malmgren L, Öberg C, den Bakker E, Leion F, Siódmiak J, Åkesson A, Lindström V, Herou E, Dardashti A, Xhakollari L, Grubb G, Strevens H, Abrahamson M, Helmersson-Karlqvist J, Magnusson M, Björk J, Nyman U, Ärnlöv J, Ridefelt P, Åkerfeldt T, Hansson M, Sjöström A, Mårtensson J, Itoh Y, Grubb D, Tenstad O, Hansson LO, Olafsson I, Campos AJ, Risch M, Risch L, Larsson A, Nordin G, Pottel H, Christensson A, Bjursten H, Bökenkamp A, Grubb A. The complexity of kidney disease and diagnosing it - cystatin C, selective glomerular hypofiltration syndromes and proteome regulation. J Intern Med. 2023 Mar;293(3):293-308. doi: 10.1111/joim.13589. Epub 2022 Dec 7. PMID: 36385445; PMCID: PMC10107454.
- Shardlow A, McIntyre NJ, Fraser SDS, Roderick P, Raftery J, Fluck RJ, McIntyre CW, Taal MW. The clinical utility and cost impact of cystatin C measurement in the diagnosis and management of chronic kidney disease: A primary care cohort study. PLoS Med. 2017 Oct 10;14(10):e1002400. doi: 10.1371/journal.pmed.1002400. PMID: 29016597; PMCID: PMC5634538.
- Chen DC, Potok OA, Rifkin D, Estrella MM. Advantages, Limitations, and Clinical Considerations in Using Cystatin C to Estimate GFR. Kidney360. 2022 Aug 23;3(10):1807-1814. doi: 10.34067/KID.0003202022. PMID: 36514729; PMCID: PMC9717651.
